Journal Mobile Options
Table of Contents
Vol. 85, No. 4, 2013
Issue release date: November 2013
Oncology 2013;85:235-240

Non-Lymphoma Hematological Malignancies in Systemic Lupus Erythematosus

Lu M. · Bernatsky S. · Ramsey-Goldman R. · Petri M. · Manzi S. · Urowitz M.B. · Gladman D. · Fortin P.R. · Ginzler E.M. · Yelin E. · Bae S.-C. · Wallace D.J. · Jacobsen S. · Dooley M.A. · Peschken C.A. · Alarcón G.S. · Nived O. · Gottesman L. · Criswell L.A. · Sturfelt G. · Dreyer L. · Lee J.L. · Clarke A.E.
aDivision of Clinical Epidemiology, McGill University Health Centre, Montreal, Que., bDepartment of Rheumatology, Toronto Western Hospital, Toronto, Ont., cDivision of Rheumatology, CHU de Québec and Université Laval, Quebec City, Que., and dDepartment of Rheumatology, University of Manitoba, Winnipeg, Man., Canada; eDepartment of Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, Ill., fDivision of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Md., gDepartment of Medicine, West Penn Allegheny Health System, Pittsburgh, Pa., hDivision of Rheumatology, Downstate Medical Center, State University of New York, Brooklyn, N.Y., iDivision of Rheumatology and jRosalind Russell Medical Research Center for Arthritis, Department of Medicine, University of California San Francisco, San Francisco, Calif., kCedars-Sinai Medical Center/David Geffen School of Medicine, University of California Los Angeles, Los Angeles, Calif., lDepartment of Rheumatology, University of North Carolina at Chapel Hill, Chapel Hill, N.C., mDepartment of Rheumatology, The University of Alabama, Birmingham, Ala., USA; nThe Hospital for Rheumatic Diseases, Hanyang University, Seoul, Korea; oDepartment of Rheumatology, Lund University Hospital, Lund, Sweden; pDepartment of Rheumatology, Rigshospitalet and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Objective: To describe non-lymphoma hematological malignancies in systemic lupus erythematosus (SLE). Methods: A large SLE cohort was linked to cancer registries. We examined the types of non-lymphoma hematological cancers. Results: In 16,409 patients, 115 hematological cancers [including myelodysplastic syndrome (MDS)] occurred. Among these, 33 were non-lymphoma. Of the 33 non-lymphoma cases, 13 were of lymphoid lineage: multiple myeloma (n = 5), plasmacytoma (n = 3), B cell chronic lymphocytic leukemia (B-CLL; n = 3), precursor cell lymphoblastic leukemia (n = 1) and unspecified lymphoid leukemia (n = 1). The remaining 20 cases were of myeloid lineage: MDS (n = 7), acute myeloid leukemia (AML; n = 7), chronic myeloid leukemia (CML; n = 2) and 4 unspecified leukemias. Most of these malignancies occurred in female Caucasians, except for plasma cell neoplasms (4/5 multiple myeloma and 1/3 plasmacytoma cases occurred in blacks). Conclusions: In this large SLE cohort, the most common non-lymphoma hematological malignancies were myeloid types (MDS and AML). This is in contrast to the general population, where lymphoid types are 1.7 times more common than myeloid non-lymphoma hematological malignancies. Most (80%) multiple myeloma cases occurred in blacks; this requires further investigation. © 2013 S. Karger AG, Basel

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Bernatsky S, Clarke A, Petri MA, et al: Further defining cancer risk in systemic lupus: updated results in an expanded international multi-centre cohort. J Autoimmun 2013, in press.
  2. Howlader N, Noone AM, Krapcho M, et al (eds): SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesda, National Cancer Institute, 2009.
  3. Knowling MA, Harwood AR, Bergsagel DE: Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone. JCO 1983;1:255-262.

    External Resources

  4. Landgren O, Linet MS, McMaster ML, Gridley G, Hemminki K, Gold LR: Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: A population-based case-control study. Int J Cancer 2006;118:3095-3098.
  5. Anderson LA, Gadalla S, Morton LM, Landgren O, Pfeiffer R, Warren JL, Berndt SI, Ricker W, Parsons R, Engels EA: Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer 2009;125:398-405.
  6. Linet MS, McLaughlin J, Harlow SD, Fraumeni JF: Family history of autoimmune disorders and cancer in multiple myeloma. Int J Epidemiology 1988;17:512-513.
  7. Canoso JJ, Cohen AS: Malignancy in a series of 70 patients with systemic lupus erythematosus. Arthritis Rheum 1974;17:383-390.
  8. Pehamberger H, Diem E, Konrad K: Systemic lupus erythematosus with multiple myeloma. Acta Derm Venereol 1978;58:527-530.

    External Resources

  9. Jordan E, Burnstein SL, Calabro JJ, Henderson ES: Multiple myeloma complicating the course of seronegative systemic lupus erythematosus. Arthritis Rheum 1978;21:260-265.
  10. Butler RC, Thomas SM, Thompson JM, Keat AC: Anaplastic myeloma in systemic lupus erythematosus. Ann Rheum Dis 1984;43:653-655.

    External Resources

  11. Solary E, Caillot D, Guy H, Olsson NO, Tanter Y, Chalopin JM: Systemic lupus erythematosus occurring in a patient with multiple myeloma. Arthritis Rheum 1986;29:933-934.
  12. Sendagorta E, Matarredona J, Brieva JA, Rodriguez ML, Ledo A: Systemic lupus erythematosus in association with smoldering multiple myeloma. J Am Acad Dermatol 1987;16:135-136.

    External Resources

  13. Umemura T, Hirai S, Ohashi M: Systemic lupus erythematosus with multiple myeloma. Nihon Hifuka Gakkai Zasshi 1988;98:1495-1503.

    External Resources

  14. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 30-1995. A 69-year-old woman with lupus erythematosus and painful skin lesions of the feet. N Engl J Med 1995;333:862-868.
  15. Afeltra A, Amoroso A, Garzia P, Addessi MA, Pulsoni A, Bonomo L: Systemic lupus erythematosus and multiple myeloma: a rare association. Semin Arthritis Rheum 1997;26:845-849.
  16. Xu Y, Wiernik PH: Systemic lupus erythematosus and B cell hematologic neoplasm. Lupus 2001;10:841-850.
  17. Lee S, Lee S, Kim Y, Park M, Lee J, Kim H: A case of multiple myeloma in a patient with systemic lupus erythematosus. J Korean Rheum Association 2002:325-329.
  18. Vaiopoulos G, Konstantopoulos K, Mantzourani M, Kaklamanis P: Multiple myeloma associated with systemic lupus erythematosus. Leuk Lymphoma 2003;44:373-374.
  19. Urbanska-Rys H, Robak E, Kordek R, Bartkowiak J, Rieske P, Wozniacka A, et al: Multiple myeloma in a patient with systemic lupus erythematosus, myasthenia gravis and non-familial diffuse palmoplantar keratoderma. Leuk Lymphoma 2004;45:1913-1918.
  20. Bila J, Suvajdzic N, Elezovic I, et al: SLE and IgA multiple myeloma: a rare association? Med Oncol 2007;24:445-448.
  21. Maamar M, Tazi MZ, Harmouche H, Adnaoui M, Aouni M, Maaouni A: Systemic lupus erythematosus and multiple myeloma: an uncommon association. Two cases and literature review. Clin Exp Rheumatol 2008;26:667-670.

    External Resources

  22. Okoli K, Irani F, Horvath W: Multiple myeloma and systemic lupus erythematosus in a young woman. JCR 2009;15:292-294.
  23. Choi JW, Han SW, Kwon KT, Kim GW: Early onset multiple myeloma in a patient with systemic lupus erythematosus: a case report and a literature review. Clin Rheumatol 2010;29:1323-1326.
  24. Frohlich K, Holle JU, Aries PM, Gross WL, Moosig F: Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma. Ann Rheum Dis 2011;70:1344-1345.
  25. Anderson LA, Pfeiffer RM, Landgren O, Gadalla S, Berndt SI, Engels EA: Risks of myeloid malignancies with autoimmune conditions. B J Cancer 2009;100:822-828.
  26. Löfström B, Backlin C, Sundström C, Hellström-Lindberg E, Ekbom A, Lundberg IE: Myeloid leukaemia in systemic lupus erythematosus - a nested case-control study based on Swedish registers. Rheum 2009;48:1222-1226.
  27. Juliusson G, Antunovic P, Derolf A, Lehmann S, Möllgård L, Stockelberg D, Tidefelt U, Wahlin A, Höglund M: Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009;113:4179-4187.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50